Other substances

Bevacizumab

An anti-VEGF antibody.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
7
 AI-suggested references
5
 Clinical trials

General information

Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor, which is involved in e.g. angiogenesis, lymphangiogenesis, and tumour growth. It is used in the treatment of cancer (DrugBank) or age-related macular degeneration (Drugs.com). It is also under investigation for COVID-19-related severe lung complications (DrugBank). Bevacizumab is in the World Health Organization Model List of Essential Medicines.

Bevacizumab on Wikipedia

Marketed as

AVASTIN; AYBINTIO; EQUIDACENT; MVASI; ZIRABEV

 

Structure image - Bevacizumab

Supporting references

Link Tested on Impact factor Notes Publication date
Efficacy and tolerability of bevacizumab in patients with severe Covid-19
Severe severity Antibody Cohort study 		Severe COVID-19 patients 12.12

Administration of the antibody in severe COVID-19 patients was associated with statistically significant improvement of oxygenation by day 1 (by day 7 only with numerical improvement in the Chinese subgroup; statistically significant in the Italian subgroup), improvement in oxygen-support status in 92% of patients within 28-day follow-up, significant improvement in chest radiological findings at day 7, and resolution of fever in 93% of febrile patients within 3 days. Adverse effects were manegeable. Sample size: 26 + 26 external control. Dosage: A single 7.5 mg/kg dose. Primary outcome: Changes of PaO2/FiO2 at days 1 and 7.


 Feb/05/2021

AI-suggested references

Link Publication date
The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection.
Jan/31/2022
Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019
Jun/23/2020
In-silico network-based analysis of drugs used against COVID-19: Human well-being study.
Jan/21/2021
COVID-19 Coronavirus-Induced Atypical Pneumonia: Efficacy of the Monoclonal Antibody Bevacizumab in Moderate to Severe Cases
Apr/09/2022
Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh
May/20/2020
Clinical trials on drug repositioning for COVID-19 treatment
Feb/08/2022
Distance based and bond additive topological indices of certain repurposed antiviral drug compounds tested for treating COVID-19.
Feb/20/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04305106 Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT Unknown status Not Applicable Mar/17/2020 Jul/31/2020
  • Alternative id - QLEmer
  • Interventions - Drug: Bevacizumab
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Qilu Hospital of Shandong University, Jinan, Shandong, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 140
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - The time from randomization to clinical improvement
NCT04822818 EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19 Recruiting Phase 3 Apr/17/2021 Jun/01/2022
  • Alternative id - APHP200375-BEVA
  • Interventions - Drug: BEVA+SOC|Drug: SOC
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hôpital TENON, Paris, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 174
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - The time to recovery for a category 0 to 5 on the WHO Progression scale|Clinical status on the OMS Progression scale|Overall survival|Ventilator free days|High flow free days|Time to oxygen supply weaning|Changes in VEGF plasma levels|Comparison of the incidence of Grade 3 or 4 events will be will be described in each group with their 95% CI|Proportion of Adverse Event
NCT04344782 Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort Not yet recruiting Phase 2 Apr/15/2020 Nov/30/2020
  • Alternative id - APHP200389-7
  • Interventions - Drug: Bevacizumab Injection
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 130
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of surviving patients without need for intubation for respiratory support|Saturation of Oxygen in the blood (SaO2)|Arterial oxygen partial pressure (paO2)|Ratio of arterial oxygen partial pressure to fractional inspired oxygen (paO2/FiO2)|CT-scan score|dyspnea|overall survival|admissionn to the intensive care unit (ICU)|incidence of mechanical ventilation|hospital length of stay|incidence of adverse event|VEGF plasma concentration
NCT04954014 Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients Terminated Phase 2 Sep/01/2020 Aug/31/2021
  • Alternative id - BEVACOR
  • Interventions - Drug: Bevacizumab|Drug: BAT
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Universitario Reina Sofía, Córdoba, Córdona, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 21
  • Age - 18 Years to 90 Years   (Adult, Older Adult)
  • Outcome measures - Mortality|PaO2/FiO2|Clinical improvement according to scale recommended by WHO for COVID19|Time to clinical improvement as stated in the National Early Warning Score 2 (NEWS)|Time to improvement of oxygenation|Time to improvement of Sp2/O2 ratio regarding the worst Sp2/O2 ratio obtained before bevacizumab treatment.|Time to absence of oxygen need to maintain a saturation equal or over 93%|Favorable radiological evaluation.
NCT04275414 Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia Completed Phase 2 Feb/15/2020 May/02/2020
  • Alternative id - QLEmer20200214
  • Interventions - Drug: Bevacizumab Injection
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 27
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio|Rate of improvement of oxygen-support status|The change of areas of pulmonary lesions shown on chest radiological imaging (chest CT or X-ray)|Blood lymphocyte counts|Level of CRP|Level of hs-CRP|All-cause mortality|Discharge rate
Export (.csv)